Evaluation of Insulin Lispro U-200 Absorption via Patch Insulin Pump in a Rabbit Model of Type 1 Diabetes
Project no. 32596 · Status: Kapanmış (Yayın bekleniyor) · 2024
Summary
<p>Diabetes Mellitus is a chronic and progressive disorder that results from insufficient insulin secretion from the pancreas or the inability of insulin to exert its effects, leading to persistent hyperglycemia. Tight glycemic control remains a cornerstone in the management of Diabetes Mellitus.</p><p>Omnipod® pumps are tubeless, wearable devices that are conventionally filled with 2 mL reservoirs of U-100 rapid-acting insulin analogs and are intended for 3-day use (1). While their set-free design provides convenience to patients, the limited reservoir capacity may be insufficient for individuals requiring high daily insulin doses. To address this limitation, concentrated insulin formulations have been developed. Utilizing concentrated insulin in Omnipod® pumps could allow for greater insulin content within the device.</p><p>To our knowledge, this concept has not been previously studied, and the present work may contribute to the literature in the following ways:</p><ol><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>If the feasibility of using concentrated U-200 insulin in Omnipod® pumps is demonstrated, this would provide a basis for further clinical investigations in humans. Successful application in patients could reduce the frequency of pod replacement, thereby improving patient comfort and offering potential cost advantages.</li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>Conversely, if technical or pharmacological issues emerge—such as insulin precipitation within the reservoir or impaired subcutaneous absorption—our findings would still provide valuable negative data, demonstrating that this approach is not viable.”</li></ol>